Optiscan and ACL Join Forces to Revolutionize Real-Time Digital Pathology
Optiscan Imaging has entered a three-year strategic collaboration with Australian Clinical Labs to validate and deploy its InForm™ digital pathology platform, aiming to transform diagnostic workflows with real-time tissue analysis.
- Three-year collaboration agreement between Optiscan and Australian Clinical Labs
- Real-world validation and testing of InForm™ digital pathology device in ACL labs
- Creation of a comprehensive image databank for pathologist training and regulatory submissions
- Accelerated commercial readiness and regulatory pathway in Australia and the US
- Potential to enhance diagnostic accuracy and streamline pathology workflows
Strategic Partnership to Advance Digital Pathology
Optiscan Imaging Ltd (ASX – OIL) has announced a significant three-year collaboration with Australian Clinical Labs (ASX – ACL), a leading pathology services provider in Australia. This partnership is designed to accelerate the deployment and real-world validation of Optiscan’s InForm™ digital pathology platform, a cutting-edge technology that enables real-time, high-resolution digital imaging of tissue samples at the point of care.
The collaboration grants Optiscan access to ACL’s extensive network of 50 accredited laboratories and over 1,200 collection centers nationwide. This infrastructure will allow Optiscan to test and refine its device within active pathology environments, ensuring the technology meets the practical needs of pathologists and laboratory technicians.
Building a Robust Image Databank and Training Platform
A key component of the partnership is the creation of a comprehensive image databank comprising diverse human tissue samples and associated pathologies. This databank will serve multiple purposes – it will support pathologist training, enhance the accuracy of diagnostic workflows, and underpin regulatory submissions in both Australia and the United States.
By integrating the InForm™ device into ACL’s flagship anatomical pathology laboratory in Western Australia, Optiscan aims to validate its technology under real-world conditions. This step is crucial for optimizing the device’s performance and accelerating its commercial readiness.
Transforming Pathology with Real-Time Digital Insights
Optiscan’s CEO, Dr Camile Farah, highlighted the strategic importance of the collaboration, emphasizing its dual benefits – rapid validation in operational labs and support for regulatory approval processes. The partnership aligns with Optiscan’s vision to revolutionize pathology by delivering immediate microscopic insights, potentially improving diagnostic speed and accuracy while reducing costs.
ACL’s Medical Director, Associate Professor Tony Landgren, expressed enthusiasm for the collaboration, noting its potential to enhance diagnostic workflows through data-driven, real-time analysis. This reflects a broader industry trend towards digital transformation in healthcare diagnostics.
As the collaboration progresses, both companies plan to provide regular updates on milestones achieved, signaling ongoing momentum in the development and adoption of digital pathology technologies.
Bottom Line?
This collaboration sets the stage for Optiscan’s InForm™ platform to become a pivotal tool in modern pathology, with regulatory and commercial milestones on the horizon.
Questions in the middle?
- What are the specific timelines for regulatory submissions and approvals in Australia and the US?
- How will the partnership impact Optiscan’s revenue and market penetration in the near term?
- What competitive responses might emerge from other digital pathology technology providers?